This week's issue of "The Tan Sheet" looks at what FDA's proposed "new paradigm" for nonprescription drug access might mean for the generic versions of innovative switches, given that current law would allow equivalents to bypass voluntary access restrictions and just go completely OTC.
Inside, we've got stories on Johnson & Johnson's struggles to return recalled OTCs to market under its consent decree with FDA and congressional supplement boosters considering legislation to bring FDA's new dietary ingredient draft guidance in line with DSHEA if the agency declines to pull back on the controversial document. There's also a feature on supplement firm ChromaDex and its pharma-like approach to product development.
For much more, and "The Tan Sheet's" full March 12 table of contents, click here.
"The Tan Sheet" is your source for the most comprehensive and in-depth coverage of the OTC drug and nutritional industries. Start your free trial subscription here -- no credit card required.
Your company or organization may already provide access to "The Tan Sheet." To find out if you should have access, email custcare@elsevier.com.
Also, follow "The Tan Sheet" on Twitter and Facebook.
--Dan Schiff (d.schiff@elsevier.com)
